Osteoprotegerin (OPG) is a soluble secreted protein and a decoy receptor, which inhibits a receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)/the receptor activator of NF-κB (RANK) signaling. Recent clinical studies have shown that a high-serum-OPG level is associated with unfavorable outcome in ischemic stroke, but it is unclear whether OPG is a culprit or an innocent bystander. Here we demonstrate that enhanced RANKL/RANK signaling in OPG −/− mice or recombinant RANKL-treated mice contributed to the reduction of infarct volume and brain edema via reduced postischemic inflammation. On the contrary, infarct volume was increased by reduced RANKL/RANK signaling in OPG −/− mice and WT mice treated with anti-RANKL neutralizing antibody. OPG, RANKL, and RANK mRNA were increased in the acute stage and were expressed in activated microglia and macrophages. Although enhanced RANKL/RANK signaling had no effects in glutamate, CoCl 2 , or H 2 O 2 -stimulated neuronal culture, enhanced RANKL/RANK signaling showed neuroprotective effects with reduced expression in inflammatory cytokines in LPS-stimulated neuron-glia mixed culture, suggesting that RANKL/RANK signaling can attenuate inflammation through a Toll-like receptor signaling pathway in microglia. Our findings propose that increased OPG could be a causal factor of reducing RANKL/RANK signaling and increasing postischemic inflammation. Thus, the OPG/RANKL/RANK axis plays critical roles in controlling inflammation in ischemic brains.
Osteoprotegerin (OPG) is a soluble secreted protein and a decoy receptor, which inhibits a receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)/the receptor activator of NF-κB (RANK) signaling. Recent clinical studies have shown that a high-serum-OPG level is associated with unfavorable outcome in ischemic stroke, but it is unclear whether OPG is a culprit or an innocent bystander. Here we demonstrate that enhanced RANKL/RANK signaling in OPG −/− mice or recombinant RANKL-treated mice contributed to the reduction of infarct volume and brain edema via reduced postischemic inflammation. On the contrary, infarct volume was increased by reduced RANKL/RANK signaling in OPG −/− mice and WT mice treated with anti-RANKL neutralizing antibody. OPG, RANKL, and RANK mRNA were increased in the acute stage and were expressed in activated microglia and macrophages. Although enhanced RANKL/RANK signaling had no effects in glutamate, CoCl 2 , or H 2 O 2 -stimulated neuronal culture, enhanced RANKL/RANK signaling showed neuroprotective effects with reduced expression in inflammatory cytokines in LPS-stimulated neuron-glia mixed culture, suggesting that RANKL/RANK signaling can attenuate inflammation through a Toll-like receptor signaling pathway in microglia. Our findings propose that increased OPG could be a causal factor of reducing RANKL/RANK signaling and increasing postischemic inflammation. Thus, the OPG/RANKL/RANK axis plays critical roles in controlling inflammation in ischemic brains.
cerebral ischemia | neuroprotection | immune cells A n elevated serum osteoprotegerin (OPG) level has been reported to be associated with the severity (1, 2), subtype (2) , poor functional outcome (1) , and long-term mortality of ischemic stroke (2, 3) . However, it is still unclear why a high-serum-OPG level could result in a poor prognosis in ischemic stroke.
OPG is a soluble secreted protein that lacks transmembrane and cytoplasmic domains. It binds to a receptor activator of nuclear factor-кB ligand (RANKL) (4, 5) , whose receptor is the receptor activator of NF-κB (RANK), and inhibits RANKL/RANK signaling. The OPG/RANKL/RANK system in bone (6) and vasculature (7) is well known to work on bone metabolism (8) and vascular calcification (7) . In addition, immune cells (6, (9) (10) (11) (12) express these molecules, and this system is believed to be associated with the regulation of inflammatory and immune responses (13, 14) . RANKL is expressed in CD4
+ T cells (6) and macrophages (9, 10) , whereas OPG is expressed in mature B cells (6) and macrophages (11, 12) . RANK is expressed in macrophage and dendritic cells (6) . One of the functions of RANKL/RANK signaling in the immune system is to control the thymocyte-mediated medulla formation and the formation of self-tolerance in T cells (14) , as well as the number of regulatory T cells (Treg) (15) . Additionally, RANKL directly contributes to the regulation of proinflammatory cytokine production in macrophages (13, 16) .
Despite these characteristics of the OPG/RANKL/RANK system, its action on inflammation in central nervous system diseases has yet to be studied. Ischemic stroke is a typical acute inflammatory disease, and postischemic inflammation affects the outcome, i.e., the infarct volume (17) . These inflammatory cytokines are produced mainly from microglia in the early phase and from mixed microglia/macrophage (M/M) in the delayed phase, i.e., 12-24 h after ischemia, whereas neutrophilic granulocytes are not responsible for the production of those inflammatory cytokines (17) . Because OPG/RANKL/RANK is expressed in macrophages (6, (9) (10) (11) (12) and affects inflammatory responses (13), we hypothesized that one of the mechanisms of poor outcome in high-level OPG might reflect the modulation of such postischemic inflammations by the OPG/RANKL/RANK signaling system. Interestingly, OPG, RANKL, and RANK have also been reported to be expressed in normal brain in rodents, although the distribution of their expression is controversial. Early reports showed that RANKL mRNA was expressed in neurons in the cerebral cortex (18) and that RANK (19) and OPG (5) mRNA was expressed in normal brain. However, a recent report revealed that the RANK protein was specifically expressed in neurons and astrocytes in the preoptic area and the medial septal nucleus, whereas RANKL mRNA was expressed in the lateral septal nucleus (20) . In normal brain, RANKL/RANK signaling was reported to be associated with fever and body temperature Significance Although a high-serum osteoprotegerin (OPG) level is associated with an unfavorable outcome in ischemic stroke, it is unclear whether OPG is a culprit or an innocent bystander. Here we show that the deletion of OPG and enhanced RANKL/RANK signaling contribute to the reduction of infarct volume with lower brain edema, whereas infarct volume is increased by reduced RANKL/RANK signaling in OPG −/− mice and WT mice treated with anti-RANKL neutralizing antibody. OPG, RANKL, and RANK mRNA were increased in ischemic brain and were expressed in activated microglia and macrophages. Enhanced RANKL/RANK signaling showed neuroprotective effects with reduced expression in inflammatory cytokines in LPS-stimulated neuron-glia mixed culture. Our findings propose anti-inflammatory roles for RANKL/RANK signaling in ischemic brains.
control (20) . Because body temperature is associated with the outcome in ischemic stroke, we also hypothesized that the modulation of body temperature by the OPG/RANKL/RANK system might be another mechanism behind a poor outcome in ischemic stroke. To clarify these hypotheses, we examined the action of the OPG/RANKL/RANK signaling system in a transient middle cerebral artery occlusion (MCAo) model using OPG −/− mice and treated RANK fragment crystalizable (Fc) chimera to inhibit the function of RANKL or recombinant RANKL.
Results
Effect of OPG/RANKL/RANK Signaling on Infarct Volume. Because a high-serum-OPG level is associated with stroke severity in clinical trials (1-3) , we examined the effects of OPG in ischemic brain using OPG −/− mice (Fig. 1A) . The OPG −/− mice showed a significant reduction in infarct volume compared with WT mice (Fig. 1A) , which was associated with a significant decrease in cerebral edema (Fig. 1B) . Although the differences in the structure of cerebral vessels and microcirculations could affect stroke outcome, no differences were observed in the pial arterial anastomoses in middle cerebral arteries and anterior cerebral arteries and the microcirculations in cerebral cortex between normal OPG −/− mice and WT mice (Fig. S1 ). In addition, cerebral blood flow (CBF) was also similar between OPG −/− mice and WT mice during surgery (Fig. S2A) . Although body temperature could be a critical factor for stroke outcome, there was no significant difference in the circadian rhythm of rectal temperature between OPG −/− and WT mice (Fig. S2B ) or the change in rectal temperature after MCAo (Fig. S2C ). These data indicate that OPG might work as an exacerbation factor for ischemic insult, independent of body temperature and CBF.
Because OPG is a decoy receptor for RANKL and because RANKL/RANK signaling was augmented in OPG −/− mice (21), we hypothesized that an enhancement of RANKL/RANK signaling might be responsible for the reduction of infarct volume in OPG −/− mice. To elucidate the role of this system, we examined the inhibition of RANKL/RANK signaling using an i.c.v. injection of a neutralizing anti-RANKL antibody, RANK Fc/ chimera, in OPG −/− mice. As expected, the OPG −/− mice treated with RANK Fc/chimera exhibited a significant increase in infarct volume (Fig. 1C) . To examine whether RANKL/RANK signaling would be associated with the outcome even in WT mice, RANK Fc/chimera was also injected i.c.v. in a mild ischemic model. The infarct volume was also significantly exacerbated ( Fig. 1D) , although the extent was less than that observed in OPG −/− mice (Fig. S3A) . These results suggest that RANKL/RANK signaling might act as a protective signal in the ischemic brain in both OPG −/− and WT mice. However, RANKL/RANK signaling might not be fully stimulated in WT mice due to the possibility that OPG partly blocks the RANKL/RANK signaling in WT mice.
To further examine the action of RANKL, WT mice in a severe ischemic model were treated with i.c.v. of RANKL starting at 4 h after MCAo ( Fig. 1 E and F) . The mice treated with RANKL showed a tendency to have a low mortality rate (Fig.  S3B ), a significantly lower infarct volume (Fig. 1E) , and less formation of cerebral edema (Fig. 1F ). Similar to OPG −/− mice, no differences in CBF were observed during the surgery (Fig.  S4A) . Because a single i.c.v. injection of RANKL was reported to affect the core body temperature (20) , we examined the change of core body temperature using data loggers (Fig. S4 B-D) . The core body temperature was not affected by the i.c.v. injection of RANKL in normal mice ( Fig. S4B ) and mice exposed to MCAo ( Fig. S4 C and D) . These results indicated that the stimulation of RANKL/RANK signaling resulted in a reduction of ischemic injury without changes in body temperature or CBF.
Temporal Profile of RANK, RANKL, and OPG mRNA Expression. Next, we examined the temporal expression of RANK, RANKL, and OPG mRNA in the ischemic brain in WT mice (Fig. 2) . RANK mRNA was increased starting at 4 h after MCAo and peaked at 12 h after MCAo. RANKL and OPG mRNA showed a biphasic profile. The peak of RANKL expression occurred at 7 and 48 h after MCAo, and OPG expression peaked at 12-24 and 72 h after MCAo. In OPG −/− mice, RANK and RANKL mRNA were also increased after MCAo ( Fig. 2 A and B) although the expression level of RANK was lower than that in WT mice ( Fig.  2A) . Thus, OPG, RANKL, and RANK were up-regulated in the acute phase of cerebral ischemia. Immunohistochemistry showed that RANK, RANKL, and OPG were expressed in F4/80-positive or Iba1-expressing M/M in the border between the infarct and intact areas, whereas the nonischemic hemisphere showed no expression of RANK, RANKL, and OPG ( Fig. 3) . OPG −/− mice also showed expression of RANK and RANKL in M/M in the ischemic hemisphere (Fig. S5 ). These data indicate that OPG, RANKL, and RANK work primarily in M/M in the acute stage of ischemic brain.
Expression of Inflammatory Cytokines in the Ischemic Brain. Because inflammatory cytokines produced from microglia have modifying effects on the infarct volume in the early phase of cerebral ischemia (17), we hypothesized that RANKL/RANK signaling in microglia modulated the inflammatory cytokine expression. As expected, OPG −/− mice showed a significantly lower expression of interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS) and a lower expression of tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), and monocyte chemotactic protein-1 (MCP-1), whereas the expression of arginase 1 (Arg1) was higher (Fig.  4A) . Moreover, the number of F4/80 positive cells in ischemic brain was significantly lower in the OPG −/− mice (Fig. 5 ). When RANK Fc/chimera was intracerebroventricularly injected in OPG −/− mice, a higher expression of mRNA was observed in RANK Fc/chimera-treated mice in IL-6, TNFα, IL-1β, MCP-1, and iNOS, but not in Arg1 (Fig. S6) . RANKL-treated mice in WT mice showed a significant reduction of IL-1β and MCP-1 and a lower expression in both IL-6 and TNFα (Fig. 4B) . However, RANKL treatment did not affect the expression of iNOS and Arg1. These results indicate that RANKL/RANK signaling had anti-inflammatory properties in postischemic injury.
RANKL Inhibited Toll-like receptor 4-Mediated Neuronal Death in
Neuron-Glia Mixed Cultures. In postischemic inflammation, endogenous danger signals, such as high-mobility group box 1 (HMGB-1) and peroxiredoxin family proteins, were reported to be responsible for exacerbating the ischemic insult (22) . Because Toll-like receptor 4 (TLR-4) is one of the receptors for these molecules (23), we examined the effect of RANKL on neuronal cell death induced by a TLR-4 ligand and LPS using neuron-glia mixed culture. In the neuron-glia culture, RANK expression was observed in Iba1-positive microglia (Fig. S7) . When LPS was added to the mixed culture, the number of MAP-2 neurons that survived was decreased, whereas RANKL pretreatment for 24 h prevented neuronal death (Fig. 6 A and B) . Because LPS indirectly causes neuronal death by increasing the expression of inflammatory cytokines produced from activated microglia (24), we examined the expression of IL-6 and TNFα in cultured medium (Fig. 6C) . Although RANKL itself did not affect the expression of those cytokines, RANKL pretreatment prevented the production of IL-6 and TNFα stimulated by LPS (Fig. 6C) . To exclude the possibility of neuroprotection of RANKL through the direct action on neurons, the effect of RANKL was examined in primary neuronal cultures (Fig. S8) . We examined the direct neuroprotective effects of RANKL in a hypoxic model induced by CoCl 2 . However, no neuroprotective effects of RANKL were observed (Fig. S8A) . We further examined the effects of RANKL in glutamate toxicity and H 2 O 2 -induced oxidative stress using an increased dose of RANKL (Fig. S8 B and C) . Similarly, no direct neuroprotective effects of RANKL were observed. These data suggest that the neuroprotective effects of RANKL are not through its direct actions on neurons but instead through the inhibition of inflammatory cytokines from microglia. 
Discussion
In the present study, we demonstrate that the stimulation of RANKL/RANK signaling through the deletion of OPG or exogenous RANKL addition prevented the further exacerbation of infarct volume and cerebral edema by inhibiting the production of inflammatory cytokines. This stimulation was independent of body temperature and CBF, whereas the blockade of RANKL/ RANK signaling resulted in the exacerbation of infarct volume. OPG, RANKL, and RANK were up-regulated in M/M in the ischemic border. Because microglia are responsible for the production of inflammatory cytokines in the early phase of ischemic brain (17) and because RANK expression starts to be up-regulated at 4 h after MCAo, RANKL could act on microglia first. Thereafter, RANKL could work on M/M in the later phase because both macrophages and microglia produce inflammatory cytokines 12-24 h after MCAo (17) . Because LPS-induced neuronal death in mixed neuronal glia was prevented by RANKL through the inhibition of inflammatory cytokine production, one possible mechanism might involve an inhibitory effect of RANKL/ RANK signaling on TLR-4 signaling in activated microglia, which has been reported to be responsible for the receptor of intrinsic danger signals in the ischemic brain (25) . Similarly, in the later phase, inflammatory cytokines from macrophages might be inhibited by RANKL because a previous report demonstrated the anti-inflammatory action of RANKL in LPS-stimulated bonemarrow-derived macrophages and peritoneal macrophages (13) . Therefore, the association of high OPG with poor functional outcome in clinics (1-3) could result from the attenuated antiinflammatory function of RANKL/RANK signaling due to the higher level of OPG, although the effects of the OPG/RANKL/ RANK axis on bone metabolism (8) and vascular calcification (7) should be carefully considered. The molecular mechanisms that determine how RANKL affects TLR signaling in microglia have yet to be clarified, but one possible mechanism in the OPG −/− model could be associated with driving the alternative activation of M/M (M2) because iNOS mRNA was decreased and Arg1 mRNA was increased in the ischemic brain in OPG −/− mice. Unexpectedly, the blockade of RANKL/RANK signaling with RANK Fc chimera did not decrease the expression of Arg1 in OPG −/− mice, but we speculate that this might be due to the functional compensation in the knockout mouse instead of RANKL/RANK signaling. Further studies are necessary to clarify the mechanisms that determine how OPG deletion influences on phenotype of M/M. On the contrary, the i.c.v. injection of RANKL in WT mice did not affect the expression of iNOS and Arg1 mRNA. This finding suggests that the temporal stimulation of RANKL might have anti-inflammatory effects without changes in M/M polarization. Because the previous study showed that myeloid differentiation primary response 88 (Myd88) expression was decreased in bone-marrow-derived macrophages by recombinant RANKL treatment (13) , RANKL might work downstream of TLR signaling in both microglia and macrophages. Further studies are necessary to clarify the detailed mechanisms.
In the present study, the expression level of RANK mRNA was lower in OPG −/− mice, probably due to the chronic stimulation of RANKL in OPG −/− mice. Previous reports showed an inconsistent expression level of RANK and RANKL in OPG −/− mice compared with WT mice: increased mRNA levels of RANK and RANKL in the aorta (21) ; the same expression level of RANKL mRNA expression in osteoblasts (26, 27) ; and a decreased expression level of RANK mRNA in osteoclasts in 12-wk-old mice followed by an increased level at 20 and 28 wk (28) . From this viewpoint, the expression level of RANK and RANKL in OPG −/− might be dependent in cells or tissue.
Compared with a previous report showing the site-specific expression of RANK and RANKL in the normal brain, i.e., the preoptic area and medial septal nucleus or the lateral septal nucleus (20) , the present study showed that these molecules started to be diffusely expressed in the cerebral cortex in the ischemic border zone. These data indicate that the RANKL/ RANK axis might not work in neurons and astrocytes in the cortex but that this axis might work in the activated microglia when the brain is exposed to ischemia. This speculation is supported by the data indicating that RANKL exhibited neuroprotective effects in the mixed glia-neuron culture but not in cultured neurons from the cerebral cortex. axis could be associated with other central nervous system diseases such as multiple sclerosis and Alzheimer's disease, where activated microglia work as a deteriorative factor.
Although the role of the RANKL/RANK axis in the pathological brain has not been reported, except in the present study, its role in the control of body temperature and fever has been reported in normal rodent brain (20) . In this previous study, RANKL-injected mice (1, 10, or 100 ng single i.c.v. injection) showed the induction of fever at 6 h after injection, with the activation of specific brain regions involved in thermoregulation and induction via the COX2-PGE2/EP3R pathway (20) . In contrast, the present study demonstrated that RANKL-injected WT mice and OPG −/− mice did not show any differences in core body temperature in either normal mice or mice subjected to MCAo. Although the cause of discrepancy between the previous report (20) and the present study is still unclear, the better outcome in OPG −/− mice and RANKL-treated WT mice could not be explained by the differences in body temperature.
Although we focused on the OPG/RANKL/RANK axis in M/M in the acute stage of ischemic brain, it is possible that the OPG/RANKL/RANK axis might influence both the control of T-cell-mediated immune responses because RANKL regulates the formation of self-tolerance in T cells (14) and any immunosuppressive effects by controlling the number of Treg in allergic contact hypersensitivity responses and the development of systemic autoimmunity (15) . Because T lymphocytes are significantly increased at day 3 (29) and because Foxp3 + Treg cells work as cerebroprotective immunomodulators in the more delayed phase, i.e., 3-7 d after MCAo (30), the OPG/RANKL/RANK axis could also be associated with the regulation of T-cell-mediated immune responses in the delayed phase. Further studies are necessary to clarify the actions of the OPG/RANKL/RANK axis on the T-cellmediated immune response.
In conclusion, in the present study we demonstrate that the OPG/RANKL/RANK system might be one of the key signals regulating M/M-derived inflammatory responses in ischemic brain. Because the i.c.v. injection of RANKL a minimum of 4 h after MCAo decreased the infarct volume, RANKL/RANK signaling might be a therapeutic target to treat ischemic stroke. Although the development of a delivery system and a modification of RANKL are needed to avoid RANKL-induced osteoporosis, further studies on the OPG/RANKL/RANK system in the brain might shed light on the molecular mechanism involved in postischemic inflammation and lead to the development of new therapeutic options for ischemic stroke.
Materials and Methods
Surgical Procedure. All procedures were approved by the Institutional Animal Care and Use Committee of Osaka University. OPG −/− mice on C57Bl6/J background and C57Bl6/J mice (wild-type) were obtained from CLEA Japan, Inc.
Transient Middle Cerebral Artery Occlusion. Mice were anesthetized with isoflurane (1.4%). Cerebral blood flow was measured using a laser Doppler flowmeter (Unique Acquisition software; Unique Medical). A 6.0 monofilament surgical suture was advanced into the internal carotid artery to obstruct the origin of the middle cerebral artery. The filament was left in place for 35, 45, or 70 min and then withdrawn. Because the effect of deleting OPG was not clear in the first experiment, we chose 45 min of ischemia, which caused moderate ischemia and was suitable for observing both deteriorating and improving effects. To examine the deteriorative effect of neutralizing anti-RANKL antibody both in WT mice and OPG −/− mice, 45-and 35-min ischemic models were applied in OPG −/− and WT mice because the average infarct volume between OPG −/− and WT mice was almost the same in that ischemic duration. To assess the therapeutic effect of RANKL, 70 min of ischemia to cause a severe infarct was also applied. Only animals that exhibited a typical reduction pattern and more than 82% reduction in CBF during MCAo, in which CBF recovered by 30-80% after 5 min of reperfusion, were included in the study. In all mice, rectal temperature was kept at 37.0 ± 0.5°C during surgery and in the recovery period until animals regained consciousness. The overall mortality was 27% at 72 h after ischemia. Measurement of Body Temperature. In OPG −/− mice, body temperature was measured by rectal probe thermometer (Unique Medical) without anesthesia. Core body temperature was continuously recorded using temperature data loggers (KN Laboratories) implanted into the peritoneal cavity. The data loggers were programmed to record body temperature every 3 min with a resolution of 0.1°C. Following the implant, animals were allowed 4 d to recover.
Measurement of Infarction
Fluorescein Angiography. The structure of cerebral vessels, capillary density, and blood-brain barrier leakage was assessed using an angiographic technique with FITC-conjugated albumin (31) . The depicted brain was fixed in 4% (wt/vol) paraformaldehyde (PFA), and the image was acquired using a fluorescence stereoscope (SZX 12, Olympus). The brains were frozen, cut into 20-μm-long sections, and examined using a Nikon A1 confocal scanning laser microscope. The images were analyzed using NIS Elements software (Nikon).
Administration of Recombinant RANKL and RANK/Fc Chimera. Recombinant mouse RANKL [5 ng in 2 μL artificial cerebrospinal fluid (aCSF)] was purchased from Peprotech EC. Recombinant mouse RANK/TNFRSF11a Fc Chimera (neutralizing anti-RANKL antibody, 4 μg in 2 μL aCSF) was obtained from R&D Systems. Intracerebroventricle injection was performed using a pulled glass micropipette (anteroposterior 1.0 mm, lateral 1.2 mm from bregma, depth 1.7 mm). Recombinant RANKL was injected at 4, 24, and 48 h after MCAo. Recombinant mouse RANK/TNFRSF11a Fc Chimera was intracerebroventricularly injected 2 h before MCAo. For the controls, BSA (Nacalai Tesque) was used at the same concentration with each reagent. FITC-conjugated albumin (10 μg/2 μl, Sigma-Aldrich) was intracerebroventricularly injected at 4 or 24 h after MCAo to examine whether the injected proteins could penetrate the cortex in ischemic brain. The concentration of FITC-conjugated albumin was half that in the previous report examining the fluorescein angiography (31) . At 2 h after injection, the fluorescence was observed around the microglia in the ischemic cortex (Fig. S9) .
Real-Time RT-PCR. The ischemic hemisphere was collected at 48 h after MCAo in OPG −/− mice. With the RANKL-treatment being 70-min ischemia in WT mice, the sample was collected at 24 h because the survival rate was low in mice at 48 h (Fig. S3B) . The mRNAs were isolated using QIAGEN RNeasy Lipid Tissue Mini Kit (Qiagen), according to the manufacturer's recommendations. The cDNA reaction was performed using a High-Capacity cDNA Archive kit (Applied Biosystems) according to the manufacturer's instructions. The oligonucleotide primers used exclusively in the in vitro experiments were purchased according to the identification RANK: Mm00437135; RANKL: Mm01313944; OPG: Mm00435451; MCP1: Mm00441243; IL-6: Mm00446190; Arg1: Mm00475988; iNOS: Mm00440502; IL-17a: Mm004329618; IL-10: Mm01288386; IL-1β: Mm99999061; and GAPDH: Mm99999915 (Applied Biosystems). The 5′ nuclease assay PCRs were performed in a MicroAmp Optical 384-well reaction plate using ABI PRISM 7900 Sequence Detection System. The levels of the target genes were quantified by comparing the fluorescence generated by each sample with that of the serially diluted standard, and the target gene expressions were normalized by the level of GAPDH expression in each individual sample.
Cell Culture. Primary neuron-glial cultures were prepared from postnatal days 1-2 in C57BL/6J mice using the method of Araki with some modifications (32) . The entire cerebral cortex was dissected and minced in Neurobasal-A (Invitrogen) with B-27 supplement (Invitrogen, Neurobasal-A/B-27) after removing the meninx. Cells were treated with papain (25 U/mL) and DNaseI (25 U/mL) for 30 min at 30°C. The cells were dissociated mechanically in Neurobasal-A/B-27 with 0.25 mM Glutamax (Invitrogen) and 10% horse serum by using a siliconized Pasteur pipette. Cells were plated on polyethyleneiminecoated 24-well plates at 7 × 10 5 /well. Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO 2 . Half of the medium was replaced with Neurobasal-A/B-27 and 5% horse serum twice per week. After 9 d of plating, the cells were composed of 42 ± 5% neurons, 56 ± 5% astrocytes, and 2 ± 1% microglia. In the experiment on neural death, cells were treated with RANKL (100 ng/mL) for 24 h, and the medium was replaced with Neurobasal-A containing N2 supplement (Invitrogen, Neurobasa-A/N2), 1% horse serum, LPS (10 μg/mL), and RANKL (100 ng/mL). Cells were immunostained with MAP-2 to determine the survival of the neurons at 5 d after the addition of LPS. The images were then digitized by microscope (FSX-100, Olympus). The acquired images were converted to grayscale with GIMP 2.8.6, and the stained area was calculated using ImageJ (National Institutes of Health). In the experiment examining the expression of TNFα or IL-6, the medium was collected at 24 h after LPS stimulation. The concentration of these cytokines was checked using commercially available ELISA kits [TNFα: Quantikine Mouse TNF-α ELISA Kit (R&D systems); IL-6: Quantikine Mouse IL-6 ELISA Kit (R&D Systems)].
For the primary neuronal culture, mouse embryonic cerebral cortex neurons were obtained from pregnant C57BL/6J mice on the 18th day of gestation and cultured (33) . The cerebral cortex was dissected, and individual cells were isolated by treatment with papain and triturated in Leibovitz's L-15 medium (Invitrogen). Cells were plated on polyethyleneimine-coated 24-well plastic culture dishes with Neurobasal (Invitrogen)/B-27 (Invitrogen) with 0.25 nM Glutamax (Invitrogen) at 37°C in a humidified atmosphere of 95% air-5% CO 2 . The medium was changed on the fourth day. On day 9, the medium was changed to Neurobasal/N2 (Invitrogen) containing BSA or RANKL (10 or 100 ng/mL). Thereafter, CoCl 2 (100 μM, 48 h), glutamate (100 μM, 10 min), or H 2 O 2 (100 μM, 24 h) was added to the medium. To check cell viability, cells were assessed using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay following the manufacturer's protocol (CellTiter 96 AQueous One Solution Cell Proliferation Assay) at the following time points after the stimulation: CoCl 2 -48 h; H 2 O 2 -24 h; and glutamate-24 h.
Immunohistochemical Staining. Mice were perfused with 4% PFA, and the brain was cut into 12-μm-thick sections. For double immunostaining, these sections were fixed and then blocked. The sections were incubated with anti-F4/80 (1:50, AbD Serotec), anti-Iba1 (1:1,000, Wako), or anti-CD11b (1:100, AbD Serotec). Then, the sections were incubated with anti-rat fluorescent antibody (1:500 for F4/80 and CD11b, Alexa Flour 546, Invitrogen) or anti-rabbit fluorescent antibody (1:500 for Iba-1, Alexa Flour 546, Invitrogen). The sections were blocked again and were incubated in streptavidin/biotin blocking kit (Vector Lab, Vector Laboratories). Then they were incubated with anti-RANK antibody (1:13, R&D systems) or RANKL (1:50, eBioscience). As a negative control, the same concentration of normal control IgG (Santa Cruz) was applied. Then they were incubated in biotinylated anti-goat IgG antibody (1:200 for RANK; Vector Lab) or anti-rat IgG antibody (1:200 for RANKL; Vector Lab) followed by fluorescent streptavidin conjugates (1:1,000, Alexa 488; Invitrogen). In the immunohistochemistry for OPG, the sections were blocked with 20% horse serum and then incubated with streptavidin/biotin blocking kit (Vector Lab), followed by incubation with biotin affinity-purified polyclonal antibody for OPG (1:10, R&D Systems). Then the sections were incubated with fluorescent streptavidin conjugates (1:1,000, Alexa 488; Invitrogen).
Immunohistochemical staining was examined using Nikon A1 confocal scanning laser microscope, and the images were analyzed using NIS Elements software (Nikon). All parameters were set in a similar manner when the signal intensity was compared.
Statistical Analysis. All values are expressed as the mean ± SEM. Multiple comparisons were evaluated by ANOVA followed by Dunnett's Multiple Comparison Test. Two groups were compared using an unpaired t test. Survival rates were evaluated using a log-rank test. The core body temperatures with data loggers were analyzed by a two-way repeated-measures ANOVA with Bonferroni posttests. Differences were considered significant at P < 0.05. The statistical analysis were performed with the software Prism 5.0 (GraphPad Software).
